Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

73.52 USD -0.63 (-0.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,195,032
Open 73.21
Bid (Size) 70.58 (3)
Ask (Size) 75.50 (3)
Prev. Close 74.15
Today's Range 73.11 - 75.10
52wk Range 61.91 - 101.47
Shares Outstanding 220,890,618
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Incyte Provides Update on Parsaclisib and MCLA-145
Incyte Provides Update on Parsaclisib and MCLA-145 
From Business Wire News Releases

Performance

YTD
-0.61%
-0.61%
1 Month
-0.62%
-0.62%
3 Month
+10.47%
+10.47%
6 Month
-3.69%
-3.69%
1 Year
-26.85%
-26.85%

More News

Read More
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
From Business Wire News Releases
Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus
Tags MRUS Benzinga Small Cap
From Benzinga
Where Incyte Stands With Analysts
Tags INCY Benzinga Analyst Ratings
From Benzinga
Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo
From Business Wire News Releases
Incyte to Present at Upcoming Investor Conferences
From Business Wire News Releases
2 Beaten-Down Cathie Wood Growth Stocks to Buy and Hold For 10 Years
Tags EXAS Recent Press Releases INCY
From Motley Fool
This Biotech Is Working With Pfizer, Merck KGaA, Roche, and Other Leaders To Develop a Better Standard of Care for Breast Cancer
Tags Partner Content ONCY Oncolytics
From Benzinga
Analysts Anticipate VONV Will Reach $82
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.